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Abstract. The mucosal epithelium is a common target of damage by chronic bacterial 36 
infections and accompanying toxins and most cancers originate from this tissue. We 37 
investigated if colibactin, a potent genotoxin1 associated with certain strains  of 38 
Escherichia coli2, creates a specific DNA damage signature in infected human colorectal 39 
cells. Notably, the genomic contexts of colibactin-induced DNA double-strand breaks 40 
(DSBs) were enriched for an AT-rich hexameric sequence motif, associated with distinct 41 
DNA shape characteristics. A survey of somatic mutations at colibactin target sites of 42 
several thousand cancer genomes revealed significant enrichment of this motif in 43 
colorectal cancers (CRCs). Moreover, the exact DSB loci corresponded with mutational hot 44 
spots in cancer genomes, reminiscent of  a trinucleotide signature previously identified in 45 
healthy colorectal epithelial cells3. This work provides evidence for the etiological role of 46 
colibactin in human cancer. 47 
In humans, besides the prototypical role of Helicobacter pylori in gastric cancer4, several 48 
bacterial species have been proposed to have a tumorigenic role in CRC, including 49 
Fusobacterium nucleatum 5 and colibactin-producing strains of E. coli 6,7. Mechanistic studies 50 
have indicated distinct bacteria-induced cancer-promoting features, including the activation 51 
of inflammatory and growth-promoting signaling hubs and the induction of DNA damage 8. 52 
Genotoxins are widespread amongst bacterial species, where they participate in inter-53 
microbial competition9. Several bacterial genotoxins, such as DNA alkylators duocarmycin10, 54 
yatakemycin11 and CC-1065 as well as polymerase inhibitors distamycin12 and netropsin 13, 55 
show preferential binding to AT-rich motifs in the minor groove 14. The B2 phylogenetic 56 
group of E. coli harbors a 54 kilobase (kb)-long pks genomic island that encodes a polyketide-57 
peptide hybrid, responsible for the production of the secondary metabolite colibactin 1. This 58 
toxin has been shown to induce double-strand breaks (DSBs) in host cells, followed by the 59 
activation of the G2-M DNA damage checkpoint pathway 1. The chemical structure of several  60 
colibactin precursors 15-18 and the isolation of colibactin-dependent N3 adenine adducts from 61 
host DNA 19 have been recently described. The high-resolution mature structure of colibactin 62 
depicts a highly symmetrical molecule that contains identical cyclopropane warheads at each 63 
end, eliciting DNA cross-links 20. These DNA cross-links may be processed by depurination at 64 
sites of colibactin action 21.  65 
We set out to explore the potential specificity of colibactin-induced DNA damage by 66 
determining the characteristics of DNA breakpoints in infected human colorectal cells. 67 
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Interestingly, using a multimodal approach (Extended Data Fig. 1), we identified an infection 68 
signature that was preserved in the genomes of about 10% of human CRCs. 69 
To induce damage by colibactin, we infected human colorectal adenocarcinoma Caco-2 cells 70 
with pks+ or pks- E. coli for 3 hrs, followed by fixation of the cells (Extended Data Fig. 2A). 71 
Controls included no treatment or treatment with  DSB-inducing, topoisomerase II inhibitor 72 
etoposide (Fig. 1A). Following infection, colibactin-induced DSBs were identified using 73 
sBLISS22, a sequencing-based DSB capture method, enabling unbiased identification of DSBs 74 
at a genome-wide scale with nucleotide resolution (Fig. 1A and Methods). To verify that 75 
sBLISS was able to capture known patterns of etoposide-induced damage, the breakpoint 76 
density around transcription start sites (TSS) was determined 22-24. Indeed, an expected 77 
increase in breakpoint counts around TSSs was observed in the etoposide control (Extended 78 
Data Fig. 2B). Interestingly, unlike etoposide-induced DSBs, or those detected in the negative 79 
controls, DSBs induced upon pks+ E. coli infection failed to show any strong correlation with 80 
known particular genomic regions (Extended Data Fig. 2C) using Locus Overlap Analysis 81 
(LOLA) 25.  82 
While we hypothesized that sBLISS captured the preferred target sites of colibactin, we 83 
analyzed the nucleotide sequence context of induced DSBs (+/-10 nt) in pks+ E.coli- vs. pks- 84 
E.coli-infected cells, using discriminative motif discovery (DREME) 26 (Fig. 1B). One of these 85 
motifs, a heptamer sequence, was strongly enriched in all replicates, overlapped the break 86 
point position, and included the consensus pattern AAWWTT with a 3’ variable, single 87 
nucleotide extension (Extended Data Fig. 3A). No enrichment for AAWWTT, referred to as 88 
the colibactin damage motif (CDM) could be identified when comparing etoposide-induced 89 
DSBs to untreated controls (Extended Data Fig. 3B). In order to evaluate how strong was the 90 
enrichment of this motif over all other motifs, we compared the enrichment of short 91 
oligonucleotide sequences (i.e., pentanucleotides or hexanucleotides) around break sites 92 
following different treatments (Methods; Fig. 1C). We found that DSBs of pks+ E. coli-93 
infected cells were generally enriched in AT-rich regions. This enrichment was particularly 94 
high for the hexanucleotides AAATTT, AAAATT and AATATT, together with their 95 
complementary mates. These sequence preferences of DSBs in pks+ E. coli-infected cells 96 
were evident in comparison to both pks- E. coli-infected (Fig. 1D, top panel) and untreated 97 
cells (Extended Data Fig. 4A). This enrichment was independently detected with almost 98 
identical relative values in all four biological replicates (Extended Data Table S1). 99 
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Importantly, no meaningful sequence enrichments were observed in the comparison 100 
between pks- E. coli-infected cells and untreated cells (Fig. 1D, bottom panel). Hence, the 101 
preference for AT-rich sequences is directly linked to the action of colibactin, rather than to 102 
non-toxigenic E. coli infection. Similar enrichments were found for pentanucleotide motifs, 103 
whereby sub-patterns of AAWWTT were most strongly enriched (Extended Data Fig. 4B). 104 
Poly(dA:dT) tracts in eukaryotic genomes have been experimentally associated with genomic 105 
fragility 27. Importantly, we found that the enrichment of other AT-rich sequences was 106 
substantially weaker than that of AAWWTT (Extended Data Fig. 4C). Moreover, AT-rich 107 
nucleosome-free regions28,29 failed to show a distinct preference for AAWWTT, indicating 108 
that the motif preference is not driven by increased access of colibactin to unprotected DNA 109 
regions (Extended Data Fig. 4D).  110 
Binding of small molecules to DNA is partially determined by DNA shape characteristics 111 
(reviewed by Tse et al. 30). We predicted the DNA shape parameters for the central positions 112 
of all possible 4096 hexanucleotides and correlated them with the log2-ratios of 113 
hexanucleotide sequence enrichment at DSB positions in pks+ E. coli- vs. pks- E. coli-infected 114 
cells. Remarkably, two out of the three colibactin-specific hexanucleotide sequences 115 
(AAAATT/AATTTT and AAATTT) exhibited the narrowest minor groove widths as well as the 116 
most extreme negative electrostatic potential (Fig. 2A, Extended Data Fig. 5A). Values for 117 
DNA stiffness descriptor 31 (k_tot, see Methods) revealed that these tracts also possessed 118 
high intrinsic rigidity (Supplementary Table S1), rendering them inert to distortion. 119 
Multivariate analysis of DNA shape parameters along the full length of all possible 120 
hexanucleotides confirmed these extreme characteristics of CDM-related sequences (Fig. 121 
2B).  122 
In order to elucidate the binding between the DNA and colibactin, we built a molecular 123 
model using quantum mechanics calculations as a first structural prediction (see Methods). 124 
The optimized structures were hydrated and subjected to molecular dynamics simulations 125 
using state-of-the-art simulation conditions (see Methods for detailed parametrization). 126 
Colibactin appeared as a rather flexible molecule with an average end-to-end distance of 127 
around 13 Å (Extended Data Fig. 5B). The development of a putative model (see Methods) 128 
shows a very stable binding of colibactin to the minor groove (Fig. 2C). It displays excellent 129 
van der Waals contacts with all the groove’s walls, with the cyclopropane rings pointing 130 
towards the adenines on opposite strands (Fig. 2D). Based on the equilibrium trajectory, we 131 
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determined that the number of base-pairs involved in the binding could fluctuate between 4 132 
and 5, depending on the orientation of the cyclopropane ring and the carbon that alkylates 133 
the N3 of the adenines (Fig. 2D, enlargement). In all cases, colibactin fitted perfectly into the 134 
narrow minor groove of the targeted sequences and adopted a spatial arrangement with a 135 
distance of around 4-5.5 Å between N3 and the center of mass of the cyclopropane, which 136 
would facilitate N3 alkylation. These results and further analysis of sequence enrichment 137 
(Extended Data Fig. 5C) indicate that apart from the presence of adenines in a distance of 3-4 138 
base-pairs on opposite strands and global DNA shape parameters (see above), the presence 139 
of central A/T dinucleotides also influenced colibactin binding.  140 
Using our approach depicted in Extended Data Fig. 1C, we investigated whether a specific 141 
mutational signature associated with this sequence exists in cancers that have been 142 
experimentally connected to pks+ E. coli infection 6,32. Thus, we used whole-exome 143 
sequencing data from CRC samples 33 (WXS project, n=619) and various databases (TCGA 144 
project, https://www.cancer.gov/tcga, 10,224 tumor cases in 24 cancer types, n=553 for 145 
CRCs) to test whether somatic mutations are specifically enriched in the sequences 146 
constituting the CDM (Methods). We found that mutation rates in AAWWTT motifs were 147 
enriched as compared with all other WWWWWW motifs in CRCs in both analyzed data sets 148 
(Methods, Fig. 3A, Extended Data Fig. 6A). We also observed enrichment at AAWWTT motifs 149 
in some other cancers (e.g., stomach cancer and uterine corpus endometroid cancer) and in 150 
cancers containing polymerase epsilon (POLE) mutations (Extended Data Fig. 6A). A thorough 151 
inspection of mutated motifs in these cancers, however, indicated that at least some of this 152 
enrichment could be attributed to other mutational processes also affecting the same motif 153 
(Extended Data Fig. 7A, B). 154 
We validated the findings from the WXS data in another cohort of CRC samples, assessed by 155 
whole genome sequencing (WGS) 34, and analyzed the enrichment of mutations in CDM-156 
related sequences for 200 tumors, including 184 microsatellite-stable (MSS), 3 POLE-157 
mutated and 13 microsatellite-instable (MSI) cases. This analysis was run in a similar manner 158 
to the WXS data analysis; however, each sample was analyzed separately instead of pooling 159 
the samples into sub-cohorts, so as to identify motif enrichment and mutational loads in 160 
individual samples. We found significant (Mann-Whitney-U test, p<0.05, FDR <20%) 161 
enrichment of mutations at colibactin-specific pentanucleotide sequences as compared with 162 
other sequences with the same length and A/T content in 3/3 POLE-mutated samples and 163 
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48/184 (26%) MSS cases, but not in MSI cases (Fig. 3B). We further found similar 164 
enrichments in MSS samples by probing for colibactin-specific pentanucleotide 165 
(AAATT/AAAAT) and hexanucleotide sequences (Fig. 3B and Extended Data Fig. 8A), whereby 166 
pentanucleotide sequences showed less enrichment in MSI cases. . The median number of 167 
mutations in MSS samples at the pentanucleotide motifs was 963 (range: 66-11876), 168 
corresponding to a median proportion of 6.7% (range: 3.9-44.7%).  169 
We next compared mutations at the AAWWTT motifs to established mutational signatures 170 
(Extended Data Fig. 1C) that have been previously deduced in pan-cancer analyses 35 and 171 
normal colorectal epithelial cells 3. To this end, we derived a theoretical single base 172 
substitution (SBS) signature based on the frequency of trinucleotide sequences, assuming a 173 
uniform distribution of T>A, T>C and T>G mutations across the motifs (Methods, Fig. 3C). 174 
Our comparison showed the highest similarity (cosine correlation coefficient 0.8) with SBSA, 175 
an SBS previously identified in healthy colonic mucosa 3. This signature is mainly 176 
characterized by T>C mutations at ATA, ATT and TTT trinucleotides and T>G mutation at TTT 177 
3. A total of 18 out of 184 MSS CRC cases (9.8%) showed SBSA contributions to the total 178 
mutational load that was greater than 5%. SBS exhibiting preferential nucleotide changes at 179 
the same trinucleotides (SBS41, SBS57, SBS28) showed similarities as well (Fig. 3C). The 180 
estimated contributions of SBSA to the total mutation load in the WGS of the CRC cohort 181 
correlated significantly with the respective proportion of mutated CDMs (Fig. 3D). This 182 
finding suggests the SBSA trinucleotide signature could be a surrogate of the colibactin-183 
specific mutational signature. Interestingly, we observed that the proportion of mutations at 184 
CDMs was particularly enriched in sigmorectal tumor sites (Figure 3E, Kruskal-Wallis test, p 185 
<0.001).  186 
To assess whether mutations in CDM could contribute to tumorigenesis by affecting pan-187 
cancer driver genes, we searched for such mutations in the TCGA dataset. Intriguingly, CDM-188 
associated driver gene mutations were identified in 18/286 (6.9%) of colon adenocarcinoma 189 
cases and in 8/89 (9.0%) of rectal adenocarcinoma cases, amongst which 10 out of 28 190 
mutations were identified in the APC gene (Fig. 3F). Interestingly, we also observed frequent 191 
mutations in driver genes of other cancer types, of which the respective tissue might have 192 
been exposed to E. coli infection (Extended Data Fig. 8B and Supplementary Table 2).  193 
We hypothesized that determining the exact ends of colibactin-induced DSBs (Extended Data 194 
Fig. 1D) could provide additional information on the resulting mutational signature. Thus, we 195 
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devised a method for detecting the authentic 5’ ends of a DSB in both forward and reverse 196 
directions (Fig. 4A, Extended Data Fig. 9A), which could discriminate between blunt-ended 197 
DSBs and DSBs with 5’ or 3’ overhangs (Extended Data Fig. 9A). The approach was validated 198 
using published BLISS data from a cell line that contained an inducible endogenous AsiSI 199 
restriction enzyme 36 (Extended Data Fig. 9B, Methods). To identify colibactin-specific break 200 
patterns, we assessed the positional distribution of identified DSB ends at three CDM-related 201 
sequences and three control sequences of the same length and similar AT content (Fig. 4B). 202 
All sequences revealed similar profiles of DSB ends in control pks- E. coli-infected cells and 203 
untreated cells (Fig. 4B, C). Conversely, in pks+ E. coli-infected cells, we noticed a distinct 204 
positional increase of DSB ends in colibactin-specific AAWWTT motifs as compared to control 205 
sequences (Fig. 4B, C). Interestingly, the observed colibactin-specific positional end point 206 
increases suggest an action of colibactin resulting in 5’ overhangs of 2 nucleotides, with a 207 
preference of end points downstream of positions 2 and 5 in the hexamer motif of the 208 
forward and reverse strands, respectively.  209 
Next, we explored (Extended Data Fig. 1D) a possible relationship between the positions of 210 
colibactin-induced damage and mutational changes in MSS CRC patients of the WGS cohort 211 
34. By comparing the 20 tumors with the highest vs. lowest mutational burden at CDMs, we 212 
identified the highest number of  mutations at positions 2 and 5 in the CDM-related 213 
sequences AAAATT and AATATT (Fig. 4D). For the AAATTT sequence motif, we found a 214 
broader distribution of mutated nucleotide positions, compatible with the relatively broader 215 
distribution of DSB sites (Fig. 4D). The mutational changes at positions 2 and 5 nicely 216 
correlated with the experimentally-deduced downstream (5’>3’) break ends, which could be 217 
the result of single-strand breaks downstream (5’>3’) to the damaged bases (Fig. 4E). 218 
Mutational changes at those positions included mainly T:A>C:G. In agreement with previous 219 
information on SBSA3, we found that T:A>C:G mutations at CDM had a higher average allelic 220 
frequency than similar changes at other motifs (two-sided Mann-Whitney-U test, p <0.001) 221 
or than mutations attributable to the age-dependent signature SBS135 (two-sided Mann-222 
Whitney-U test, p <0.001), indicating a mutational process happening early in carcinogenesis 223 
rather than an ongoing process. 224 
Using an unbiased global approach to assess the specificity of colibactin-induced DSB 225 
formation, we identified the motif AAWWTT as the preferred target. Most but not all 226 
sequences constituting the CDM exhibited extreme physical values of the DNA duplex, 227 
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characterized by a very narrow minor groove width, a highly negative electrostatic potential 228 
and a pronounced stiffness. Even though a definitive understanding of the binding 229 
conformation requires further support from 3D structural analysis, the 3D model provides 230 
valuable insight. In concert with our experimental data, this model suggests that colibactin, 231 
using its two cyclopropane groups, selectively targets two adenines on opposite strands at a 232 
distance of ~4 nt in the motif AAWWTT. This model is in perfect agreement with the 233 
observed DSB ends generated by colibactin’s action and the position of mutations in the 234 
CDMs of the relevant cancer genomes. Accordingly, our data illuminate the mechanism of 235 
DSB formation by colibactin and provide a firm link to the presence of a distinct mutational 236 
signature in human cancer genomes, most specifically in colorectal carcinoma.  237 
Recent mechanistic data suggest that, following the formation of N3 adenine adducts 19, 238 
colibactin’s DNA cross-links undergo depurination via beta-elimination 21. This may involve 239 
the action of glycosylases 37. Our exact DSB end point determination by sBLISS suggests that 240 
cleavage occurs immediately downstream (5’>3’) of positions 2 and 5 of the putatively-241 
alkylated adenines on the opposing strands. Thus, cleavage results in staggered ends with 5’ 242 
overhangs of two nucleotides each (Extended Data Fig. 1E). Most intriguingly, the identified 243 
cleavage positions next to the alkylated adenines perfectly match the location of CDM-244 
associated mutations in CRCs. The ultimate manifestation of mutations in the damaged 245 
lesions has been suggested to involve the action of error-prone translesion polymerases in 246 
opposition to the damaged bases or apurinic sites 38. Alternatively, other host DNA repair 247 
mechanisms might act, such as nucleotide excision of alkylated adenines 39. This could lead 248 
to DSBs, resection of break ends, or complete repair, amongst others; however, details of 249 
the mutational process requires further investigation.  250 
Most strikingly, we were able to demonstrate the enrichment of mutations in the CDMs of 251 
cancer genomes. Owing to the unique features of these mutations, we propose that this 252 
provides definitive evidence of a bacterial infection signature in human cancer. Further, our 253 
observation of colibactin-related driver mutations in CRCs is suggestive of a potential causal 254 
relationship. Typically for CRC, the initial driver mutations cause an intensification of Wnt 255 
signaling, consistent with mutations in APC40. In fact, our search for driver mutations in the 256 
CDM of cancers revealed enrichment in such driver genes, particularly APC – thus 257 
corroborating the causative role of pks+ E. coli in colon cancer.  258 
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An intriguing speculation is that, besides pks+ E.coli, other bacteria, such as Klebsiella 259 
pneumoniae potentially harboring the same genotoxin island2, might be involved in human 260 
carcinogenesis as well. While current data only provide weak evidence for a broader impact 261 
of the colibactin in other cancers, this possibility remains as an important perspective for 262 
future investigation.  263 
 264 
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Figure Legends 394 
 395 
Fig.1. Colibactin preferentially damages DNA in specific AT-rich motifs 396 
(A) Illustration of the sBLISS protocol for the identification of colibactin-induced DSBs. (B) We 397 
employed DREME to analyze motif enrichment around DSBs in pks+ vs. pks- E. coli-infected 398 
cells. The sequence AAWWTT was identified as the preferred CDM among the top three 399 
enriched motifs in four independent replicates. (C) Relative enrichment of hexanucleotide 400 
sequences in close proximity to the DSB positions (±7 nt) upon different treatments was 401 
determined as the ratio of counts of a given sequence between two conditions. (D) Bars 402 
represent the mean enrichment of the top 50 DSB-associated hexanucleotide motifs (log2 403 
ratios of DSBs at each motif comparing two conditions) in pks+ vs. pks- E. coli-infected cells 404 
(top) or pks- E. coli-infected cells vs. nontreated (NT) cells (bottom), n=4 independent 405 
experiments. Insets - results for all hexanucleotides. Error bars denote the 95% confidence 406 
interval (CI) around the mean log2 ratios.   407 
 408 
Fig. 2. Colibactin-specific binding motif correspond to extreme DNA shape parameter 409 
values and electrostatic potential 410 
(A) Relations between hexanucleotide sequence enrichments (log2 ratio standardized to 1; 411 
mean of 4 independent experiments) in pks+ vs. pks- E.coli-infected cells and values of 412 
predicted DNA shape parameters for the central nucleotides of those motifs. Error bars 413 
denote the 95% CI around mean scaled log2 ratios for each hexanucleotide sequence, n=4.  414 
(B) 3D principal component analysis (PCA) visualization of the first three principal 415 
components from predicted DNA shape values for all positions in all possible 6 nt motifs. The 416 
motifs that match AAWWTT and/or show strong enrichment are highlighted: red – 417 
significant AAWWTT sequences; blue – significant non-AAWWTT sequences; grey – other 418 
sequences. Statistical significance is determined by an upper 95% CI limit of mean log2 ratio 419 
> 0.2, n=4 independent experiments.  420 
(C-D) Graphical representations of the theoretical docking of the predicted colibactin 421 
structure into its preferred sequence motif (central sequence AAATTT), showing the 422 
insertion of colibactin into the minor groove, with the double-stranded DNA as a surface (C) 423 
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or in atomic details (D). The enlargement shows a zoomed-in image of the proximity of the 424 
cyclopropane to one of the N3 atoms of the adenine, highlighting the possibility to alkylate 425 
the subsequent base-pair, depending on the carbon involved in the alkylation. 426 
 427 
Fig. 3. Several cancers show enrichment of mutations in CDMs 428 
Enrichment of SBS mutations at colibactin-specific AAATTT/AAAATT sequences in exomes of 429 
619 CRC cases 33 (A) or  at AAATT/AAAAT pentanucleotides in whole-genome data from 430 
CRC34 (B, n=200). (B) Top - differences in log2(mutations/base-pair) between colibactin-431 
specific and all other WWWWW motifs. Middle - total mutation count at CDMs. Bottom - 432 
proportions of total mutations that overlap with CDMs in MSS, MSI, and POLE-mutated 433 
cases. (A,B) Asterisks - significant difference (two-sided Mann-Whitney-U test, p < 0.05 and 434 
FDR < 20%) between CDMs and all WWWW(W) motifs. Numbers under asterisks – number 435 
of mutations overlapping AAWWTT / all mutations, [number of samples per cohort]. Error 436 
bars = 0 ± 2MAD intervals of mutation rates (mutations/base-pair) of WWWWW(W) 437 
sequences, excluding CDMs, after subtracting their mean. Dots - mutation rates for 438 
AATTT/AAAAT or AAATTT/AAAATT after mean subtraction.. Crosses - means of the CDMs. 439 
Q1-Q4 cohorts defined by the quantiles of total SNV numbers. Outliers - samples with SNV 440 
numbers significantly larger than the 95% CI in each cancer entity. POLE - polymerase epsilon 441 
mutated cases. (C) Theoretical trinucleotide change signature for uniform mutations at 442 
AAWWTT motifs (top) and the matching signature SBSA (bottom).(D) Correlation between 443 
the estimated contribution of SBSA signature per sample in 184 MSS CRCs and the 444 
proportion of total SNVs overlapping colibactin-specific pentanucleotides. (E) The proportion 445 
of mutations in CDMs depending on the tumor location (n=184 MSS CRC, Kruskal-Wallis test, 446 
p < 0.001). (F) APC  exonic somatic mutations in CDM in CRC cases from TCGA and the 447 
COSMIC database. 448 
 449 
Fig. 4 Analysis of colibactin-induced DSB break ends and mutational patterns in CDMs 450 
indicate damaged positions  451 
(A) Schematic representation of the break end determination of an arbitrary DSB 452 
configuration based on sBLISS data (see Fig. S5 for additional examples). (B) Mean 453 
proportions of break ends by the position and direction of a motif in reads (red - forward; 454 
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green - reverse) for colibactin-specific (leftmost three columns) and control motifs 455 
(rightmost three columns) in pks+ E. coli-infected cells, pks- E. coli-infected cells and control 456 
conditions, n=4 independent experiments (dots). Negative values denote mean proportions 457 
on the reverse strand of the motif. Error bars: 95% CI around mean proportions.  (C) The 458 
mean differences in break end proportions (taken from Fig. 4B) between pks+ E. coli-infected 459 
cells and pks- E. coli-infected cells, n=4. Negative values denote mean differences on the 460 
reverse strand. Error bars: 95% CI around mean differences. Only increased break end 461 
proportions in pks+ E. coli-infected cells are shown for each position. (D) The positional 462 
frequencies of nucleotide changes in CDMs found in the CRC WGS cohort. The 20 cases with 463 
the highest and lowest proportion of mutations at AAWWTT are shown. (E) The model of 464 
colibactin-induced DSB and damaged bases as derived from the data shown in this figure. 465 
Red-colored nucleotides denote damaged bases, vertical bars are single-strand breaks, which 466 
were detected by sBLISS, and the broken line denotes the inter-strand crosslink caused by 467 
colibactin action. 468 
 469 
Materials and Methods 470 
 471 
Cell line, bacterial strains, E. coli infection and etoposide-treatment 472 
Caco-2 cells (from ATCC® HTB-37TM) were cultured at 37 °C in a humidified 5% CO2 473 
atmosphere, in DMEM medium (Life Technologies, cat. number: 10938-025), supplemented 474 
with 20% FCS (Biochrom, cat. number: S0115). Contamination of Mycoplasma spp. in this 475 
immortalized cell line was excluded using the Venor®GeM OneStep PCR kit (Minerva 476 
Biolabs®, cat. number: 11-8250). To infect Caco-2 cells, an overnight liquid culture of E. coli 477 
strain M1/5 (streptomycin-resistant and colibactin-positive) and E. coli strain M1/5::ΔclbR 478 
(streptomycin-resistant and colibactin-negative) was set up. Bacteria were inoculated in 5 ml 479 
of Luria broth (LB) medium and incubated overnight at 37 °C in a shaking incubator. The 480 
overnight inoculum was diluted 1:33 in infection medium (DMEM + 10% FCS + 10 mM HEPES 481 
(Life Technologies, cat. number: 15630-056)) to obtain OD600=1 after 3 hr of incubation to 482 
give 1.5 x 109 bacteria/ml. The prepared bacteria inoculum was further diluted to reach MOI 483 
20, added to Caco-2 cells seeded previously and incubated for 3 hr at 37 °C. Medium was 484 
then aspirated and cells fixed according to the protocol for immunofluorescence or sBLISS. 485 
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For every biological replicate, positive (etoposide-treatment) and negative (no treatment) 486 
controls were included. Etoposide powder (Sigma Aldrich, cat. number: E1383) was diluted 487 
in DMSO to 50 mM and aliquots stored at -20 °C. Final drug dilutions to the concentration of 488 
50 μM were performed in pre-warmed infection medium prior to each treatment. Treatment 489 
was conducted for 3 hr at 37 °C, after which the medium was aspirated, and etoposide-490 
treated cells were fixed in the same way as E. coli-infected cells. 491 
 492 
Immunofluorescence staining 493 
Caco-2 cells grown and infected on MatTek glass-bottom dishes were washed three times 494 
with PBS (Life Technologies, cat. number: 14190-094) and fixed with 3.7% paraformaldehyde 495 
(Sigma Aldrich, cat. number: P6148) for 1 h. The cells were kept overnight in blocking buffer 496 
(3% BSA, Biomol, cat. number: 01400.100), 1% saponin (Sigma Aldrich, cat. number: 84510), 497 
2% Triton X-100 (Carl Roth, cat. number: 3051.2) and 0.02% sodium azide (Sigma Aldrich, cat. 498 
number: S2002). Blocking was followed by overnight incubation with γH2AX antibody 499 
(Phospho-Histone H2A.X (Ser139) Antibody, Cell Signaling, cat. number:  2577, 1:500 500 
dilution) at 4 °C. The next day, the MatTek dishes were washed three times with blocking 501 
buffer followed by overnight incubation with secondary antibody (Dianova, cat. number: 502 
711-035-152, 1:250 dilution) diluted in blocking buffer. Phalloidin 546 (Invitrogen, cat. 503 
number: A22283, 1:200 dilution) and Hoechst (Sigma, cat. number: H6024, 1:10000 dilution) 504 
were added for staining actin filaments and DNA, respectively. The next day, cells were 505 
washed three times with blocking buffer and coverslipped using Vectashield® Antifade 506 
Mounting Medium (Vector Laboratories, cat. number: H-1000). Images were acquired using 507 
a Leica TCS SP-8 confocal microscope and processed using ImageJ. 508 
 509 
sBLISS, an adaptation of the BLISS method 510 
DSBs were identified using the suspension-cell BLISS (sBLISS) method 41, which is an 511 
adaptation of the previously published BLISS protocol 42,43. In contrast to BLISS, where DSBs 512 
are labeled in fixed cells immobilized on microscope slides, in sBLISS DSBs are labeled in fixed 513 
cell suspensions. In brief, cells were treated/infected in culture dishes, after which they were 514 
trypsinized, counted, centrifuged and resuspended in pre-warmed medium to obtain 106 515 
cells/ml. Then, cells were fixed by adding 16% PFA (Electron Microscopy Sciences, cat. 516 
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number: 15710) to reach a final concentration of 4%. After 10 minutes, 2 M glycine 517 
(Molecular Dimensions, cat. #MD2-100-105) was added to a final concentration of 125 mM 518 
in order to block unreacted aldehydes. This was followed by two 5 min incubations, first at 519 
room temperature and then on ice, followed by two washes in ice-cold PBS. Cross-linked 520 
cells were stored in PBS at 4 °C until further processing.  521 
Next, the BLISS template was prepared. This includes (1) Cell lysis in 10 mM Tris-HCl, 10 mM 522 
NaCl, 1 mM EDTA, and 0.2% Triton X-100 (pH 8) buffer, followed by lysis in buffer containing 523 
10 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, and 0.3% SDS (pH 8); (2) DSB blunting with NEB’s 524 
Quick Blunting Kit (NEB, cat. number: E1201); (3) In situ BLISS adapter ligation using T4 DNA 525 
Ligase (ThermoFisher Scientific, cat. number: EL0011). Each BLISS adapter contained a T7 526 
promoter sequence for IVT, the RA5 Illumina RNA adapter sequence, a random 8 nt long 527 
sequence referred to as Unique Molecular Identifier (UMI) and an 8 nt long sample barcode; 528 
(4) Phenol:chloroform-based extraction of gDNA; (5) Fragmentation of isolated genomic DNA 529 
(400-600bp) using BioRuptor Plus (Diagenode). Obtained BLISS templates were stored at -20 530 
°C. 531 
The final step of the BLISS protocol was in vitro transcription (IVT) followed by NGS library 532 
preparation. First, 100 ng of purified, sonicated and differentially-barcoded BLISS template of 533 
1) etoposide-treated and non-treated cells, or 2) cells infected with pks+ E. coli or with pks- 534 
E. coli were pooled into one reaction, respectively. IVT was performed using MEGAscript T7 535 
Transcription Kit (ThermoFisher, cat. number: AMB13345) for 14 hr at 37 °C in the presence 536 
of RiboSafe RNAse Inhibitor (Bioline, cat. number BIO-65028). Next, gDNA was removed 537 
using DNase I (ThermoFisher, cat. number: AM2222), and the remaining RNA was purified 538 
with Agencourt RNAClean XP beads (Beckman Coulter). The Illumina RA3 adapter sequence 539 
was ligated to the purified RNA using T4 RNA Ligase 2 (NEB, cat. number: M0242) for 2 hr at 540 
25 °C and reverse transcription was performed with Reverse Transcription Primer (Illumina 541 
sequence) using SuperScript IV Reverse Transcriptase (ThermoFisher, cat. number: 542 
18090050) for 50 minutes at 50 °C. This was followed by heat inactivation for 10 minutes at 543 
80 °C. Finally, libraries were amplified with NEBNext High-Fidelity 2x PCR Master Mix (NEB, 544 
cat. number: M0541), the RP1 common primer and a uniquely selected index primer. 12 PCR 545 
cycles were conducted, and after that, libraries were purified according to the two-sided 546 
AMPure XP bead purification protocol (Beckman Coulter). Profiles of the libraries were 547 
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quantified on a BioAnalyzer High Sensitivity DNA chip. Libraries were sequenced as single-548 
end (1x75) reads on the NextSeq platform. 549 
 550 
Pre-processing of sequencing data 551 
Raw sequencing data were pre-processed as previously described 42. In brief, only reads 552 
which contained the expected prefix of UMI and sample barcode were kept using SAMtools 553 
44. One mismatch in the barcode sequence was allowed. Further, prefixes were trimmed, and 554 
the remaining sequences were aligned to the GRCh37/hg19 reference genome using BWA-555 
MEM 45. Reads with mapping quality scores ≤ 30 and those that were determined as PCR 556 
duplicates were removed. Finally, a BED file containing a list of unique DSB locations was 557 
generated. DSBs which fell into ENCODE blacklist regions 46, high coverage regions and low 558 
mappability regions 47 were removed. Kept positions of DSBs were further used in 559 
downstream analysis. For BLISS data of AsiSI-induced breaks  48 a similar procedure with 560 
simplified filtering was applied. 561 
 562 
Locus Overlap Analysis 563 
To identify significant overlaps of DNA DSB with genomic region sets, we used LOLA 11. We 564 
first defined whole genome as a Universe Set, which was next divided into tiles of equal 565 
lengths (1,000 nt). For each created tile, we next searched for overlaps with DSBs captured 566 
by sBLISS using the findOverlap() function. All tiles containing ≥ 10 breaks were used as a 567 
Query Set. The runLOLA() function was executed with LOLA Core databases (reduced by 568 
Tissue clustered DNase hypersensitive sites) as well as LOLA Extended databases and custom 569 
database containing non-B-DNA regions (https://nonb-570 
abcc.ncifcrf.gov/apps/site/references). Fisher’s exact test was used with a FDR ≤ 5%. 571 
 572 
Pattern identification around breakpoints 573 
We screened the +/-10 bp contexts of DSB positions produced by sBLISS using DREME49, 574 
comparing all breakpoints from pks+ E. coli-infected cells to pks- E. coli-infected cells from 575 
the same experiment, allowing for a maximum of 10 motifs per experiment with a minimum 576 
E value of less than 0.05. A similar analysis was performed for etoposide vs. untreated 577 
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control cells but allowing for up to 50 motifs per experiment. Most of the top motifs 578 
identified for pks+ E.coli- vs. pks- E.coli-infected cells were of 7 nt length; therefore the 579 
subsequent computation of enrichment log ratios for all possible oligonucleotides was done 580 
on windows of DSB breakpoints +/-7 bp and for oligonucleotide lengths of 5-7 nt. We 581 
computed the proportion of all DSB breakpoints in each sample that contained a given 582 
pattern and determined the log2 ratio of the proportion of each pattern in the test 583 
compared to control conditions of the same experiment. We observed that several of the 584 
patterns enriched only in specific experiments were very similar to the library barcode from 585 
the same experiments, indicating a priming activity of unbound sBLISS linkers. We therefore 586 
excluded all patterns matching library-specific barcodes with at most 1 mismatch from 587 
further analysis. Enriched heptamers were, in agreement with the DREME analysis, mostly 588 
the top enriched hexamers with different flanking nucleotides and are therefore not 589 
reported here. To visualize the proportion of each nucleotide per position the package 590 
seqLogo was used 50,51  591 
 592 
DNA Shape predictions 593 
DNA structures can be described in terms of base-pair and base-step parameters that consist 594 
of three translational and rotational movements between the bases or the base pairs, 595 
respectively. At the base-pair step level, DNA deformability along these six directions has 596 
been described by the associated stiffness matrix 52. From the ensemble of molecular 597 
dynamics (MD) simulations considering the tetramer environment using the newly refined 598 
parmbsc1 force field, we retrieved the 6x6 matrix describing the deformability of the helical 599 
parameters for each possible DNA tetramer. Pure stiffness constants corresponding to the 600 
six base-pair step parameters (shift, slide, rise, tilt, roll and twist) were extracted from the 601 
diagonal of the matrix, and the total stiffness (K_tot) was obtained as a product of these six 602 
constants and used as an estimate of the flexibility of each base pair step in a tetramer. For 603 
predictions of minor groove width (MGW), propeller twist (ProT), electrostatic potential (EP), 604 
helical twist (HelT) and roll (Roll) the getShape function from ‘DNAshapeR’ package was used 605 
53. Input FASTA files, containing sequences in close proximity to identified DSB (±5 nt), were 606 
extracted with a custom Python script. Central values of DNA shape parameters and EP were 607 
derived as the mean values of nucleotide at positions 3 and 4 of the motifs for MGW,ProT 608 
and EP; for stiffness, HelT and Roll the mean of the base-pair values is calculated for steps 2 609 
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to 4 in each hexamer. For the multivariate analysis of those parameters we used all values 610 
along the full 6nt of hexanucleotide sequences predicted in the same way. The interaction 611 
potential (electrostatic and van der Waals) of Na+ probes with DNA duplexes was determined 612 
using a linear approximation to the Poisson-Boltzmann equation and dielectric constant for 613 
the DNA as implemented in the CMIP program 54.   614 
 615 
Model and Molecular dynamics set up 616 
The 3D structure and protonation state of colibactin were built starting from the smile 617 
(https://pubchem.ncbi.nlm.nih.gov/compound/138805674#section=InChI) using 618 
MarvinSketch (MarvinSketch, version 6.2.2, calculation module developed by ChemAxon, 619 
http://www.chemaxon.com/products/marvin/marvinsketch/). The geometry of the model 620 
and the partial atomic charges were assigned to the structure with General Amber Force 621 
Field (GAFF) 55. Parameters and topology files were prepared with Acpype 56. The colibactin 622 
was then simulated in explicit solvent at 298 K (see below for details) for 250 ns, and along 623 
the simulation the distance between the cyclopropanes was monitored (see Extended Data 624 
Fig. 3B), to study their orientation and the overall length of the free colibactin. Using 625 
HADDOCK 2.4 57, we then built the DNA-colibactin complex. For the docking, we selected a 626 
representative structure of free colibactin along the MD simulation, with an average distance 627 
among the cyclopropanes (red line, Extended Data Fig. 3B) and an equilibrated structure of 628 
the DNA (sequence CGAAATTTCG). After the initial docking, which positioned the molecule 629 
correctly along the minor groove of the DNA, we then manually rotated the molecule slightly 630 
to improve the orientation of the cyclopropanes towards the N3 of the closest adenine using 631 
PYMOL (The PyMOL Molecular Graphics System, Schrödinger, LLC (2018)). To check the 632 
stability of this complex and to equilibrate its structure, the model was simulated (see details 633 
MD simulation below) and minimized in solution with positional restraints on the solute 634 
using our well-established multi-step protocol 58,59. The minimized structure was thermalized 635 
to 298 K at NVT, and then simulated first applying harmonic restraints of 5 kcal/mol·Å2 on 636 
the DNA structure and distance constraints between the cyclopropane and the N3 of the 637 
adenine (respectively 4 and 5 bases apart), each represented by a harmonic restraint of 2.5 638 
kcal/mol·Å2. To further check the stability of the complex, we then slowly removed the 639 
constraints and ran 10 replicas of MD simulation of the complex for a total of 500 ns by 640 
means of Molecular Dynamics simulations at NPT (P = 1 atm; T= 298K) and one MD 641 
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simulation 350 ns long. The first 10 ns of the simulations were considered as an equilibration 642 
step and were discarded for further analysis.  643 
In each MD simulation (DNA, free colibactin and their complex, respectively), we placed the 644 
solute in the center of a truncated octahedral box of TIP3P water molecules 60, neutralized 645 
by K+ ions. In each simulation, the Berendsen algorithm 61 was used to control the 646 
temperature and the pressure, with a coupling constant of 5 ps; and the SHAKE algorithm 647 
was utilized to equilibrium the length of hydrogen atoms involved in the covalent bonds 62. 648 
Long-range electrostatic interactions were accounted for by using the Particle Mesh Ewald 649 
method (14) with standard defaults, and a real-space cut-off of 10 Å. For the DNA we used 650 
the newly revised force field parmBSC1 63. All simulations were carried out using AMBER 18 651 
64, analyzed with CPPTRAJ 65 and visualized using VMD 1.9.4 66. 652 
 653 
Cancer somatic mutation data and mutation enrichment at colibactin-specific patterns 654 
We obtained somatic variant data from the TCGA Unified Ensemble "MC3" Call Set  67 (“TCGA 655 
pan-cancer dataset”) and from the supplementary data of Giannakis et al. 68. To test for 656 
enrichment of mutations at any motif, we first identified positions of all hexanucleotide 657 
motifs in the exonic portion of the genome. Somatic variants occurring at A or T bases were 658 
grouped in one of 6 classes (quartile 1-4, outlier or POLE mutated sample) depending on the 659 
total SNV number and POLE mutation status of the corresponding tumor sample. We 660 
included all cases with an exonic mutation with predicted impact on the coded protein in 661 
POLE and also those with similar mutations in the related gene POLD1 in the class of POLE-662 
mutated cases. We then computed the mutation rate for each hexanucleotide motif with 663 
respect to the number of genomic bases covered in exonic regions for the same motif. As a 664 
baseline, we established the mutation rates of all WWWWWW motifs and subtracted their 665 
mean from the mutation rate of all other hexanucleotide motifs. We then tested for 666 
significance of the mutation rate at colibactin associated AAWWTT motifs (i.e., AAATTT and 667 
AAAATT/AATTTT) compared to the remaining WWWWWW motifs using Mann-Whitney-U 668 
tests and computed the false discovery rate (FDR) using the method of Benjamini-Hochberg 669 
69. We applied a similar procedure for pentanucleotide motifs AAATT/AATTT and 670 
AAAAT/ATTTT. Reads from WGS of colorectal cancers 70 (EGA database accession code 671 
EGAS00001003010) were aligned to GRCh38 with BWA-MEM 45 and called using Mutect2 71. 672 
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All single nucleotide variant calls (PASSed by Mutect2) were used to determine the number 673 
of mutations overlapping WWWWW pentanucleotides and WWWWWW hexanucleotides 674 
and further analyzed in a similar way as for exome sequencing data on an individual sample 675 
basis. For correlation of colibactin-specific mutation load with SBSA and clinical parameters, 676 
we computed a colibactin mutation proportion. We considered colibactin mutations as all 677 
A/T > C/G mutations at 2nd and 5th position in the AAATTT, AATATT, AAAATT and AATTTTT 678 
motifs. That number was divided by all other A/T > C/G mutations outside those motifs. 679 
Somatic mutation and motif analyses with WGS CRC samples were performed with 680 
BasePlayer72. Allelic proportions of somatic variants from rectal MSS WGS CRC classified as 681 
colibactin associated (A/T > C/G mutations at 2nd and 5th position in the AAATTT, AATATT, 682 
AAAATT and AATTTTT) were compared to those of all other somatic variants  or age-related 683 
signature SBS1 associated variants  (C/G>T/A at CpG) of the same tumors using  684 
 685 
Correlation with known trinucleotide signatures 686 
Known trinucleotide SBS signatures were obtained from COSMIC  Mutational Signatures v3 73 687 
Signatures from Lee-Six et al. 74 were generated using R scripts and trinucleotide frequencies 688 
provided with this publication. We used the trinucleotide context of the three possible 689 
sequences of the AAWWTT motif (AAATTT, AATTTT and AATATT) to determine trinucleotide 690 
frequencies in those motifs. We used the reverse complement of the trinucleotide if the 691 
middle base was an A and extended the sequence by N (i.e., all possible nucleotides) for 692 
trinucleotides overlapping the end of the motif by one base. For each possible trinucleotide, 693 
we established the total number of occurrences in AAWWTT.  We assumed a uniform 694 
distribution of all possible mutations T>A/C/G nucleotide changes across all positions of the 695 
motif, and then generated a trinucleotide change signature by computing the proportion of 696 
each combination of trinucleotide and nucleotide change in AAWWTT motifs. The cosine 697 
correlation was computed between this AAWWTT signature and all known signatures in R. 698 
Contributions to known trinucleotide signatures in cancer samples were estimated using the 699 
R package deconstructSigs 75. 700 
 701 
Driver gene analysis 702 
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Entity-specific driver genes were obtained from the Catalog of Cancer Genes (Cancer 703 
Genome Interpreter, https://www.cancergenomeinterpreter.org/genes)76. Pan-cancer driver 704 
genes were obtained from a published analysis based on the TCGA cohort 77. Somatic 705 
variants from this database were classified as protein changing if the impact class was HIGH 706 
or it was MODERATE, and the protein change was classified by PolyPhen or SIFT as probably 707 
damaging or deleterious, respectively.  Somatic variants from samples of genome-wide 708 
screens other than TCGA in COSMIC78 were classified as protein changing if it had been 709 
classified as pathogenic by FATHMM or if its consequence was a frameshift deletion or a 710 
nonsense substitution. 711 
 712 
Analysis of biases in AAWWTT mutation enrichment due to other signatures 713 
We obtained frequencies of pentanucleotide changes, trinucleotide changes and 714 
trinucleotide SBS signature contributions for PCAWG samples from the PCAWG project79. We 715 
derived a theoretical AAWWTT pentanucleotide signature similar to the AAWWTT 716 
trinucleotide signature above. We projected trinucleotide changes of known cancer-717 
associated SBS signatures to trinucleotides, computing the weight of each pentanucleotide 718 
change as the weight of the corresponding central trinucleotide change in the SBS signature 719 
followed by normalization to a sum of one across all pentanucleotide changes. We computed 720 
the contribution of SBSA in all PCAWG samples using trinucleotide counts provided by 721 
PCAWG and used the contributions of all other SBS signatures as provided by PCAWG.  722 
 723 
Clinical data 724 
Limited clinical data on tumor patients  was obtained from a study by Katainen et al 70 that 725 
was reviewed and approved by the Ethics Committee of the Hospital District of Helsinki and 726 
Uusimaa (HUS). Signed informed consent or authorization from the Finnish National 727 
Supervisory Authority for Welfare and Health has been obtained for all the sample materials 728 
used. 729 
 730 
Break end analysis 731 
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DSB positions were derived from sBLISS estimated breakpoints in a strand-specific manner as 732 
the middle of the positions of the first base in the mapped genomic fragment and the last 733 
base in 5’ direction (i.e. the direction of the linker). Genomic positions of oligonucleotide 734 
patterns of interest were identified in GRCh37. Breakpoints falling with the pattern +/- 2bp 735 
flanking regions were kept and the relative position of the breakpoint in the 5’-3’ motif were 736 
computed. Each strand-specific breakpoint was classified as mapping to the strand 737 
containing the motif in forward or backward direction. Counts for each relative pattern 738 
position and motif direction were computed for each pattern and normalized by the total 739 
number of breaks mapping to this pattern for each sample. Differences between normalized 740 
counts were computed for each experiment between pks+ E. coli and pks- E. coli conditions. 741 
 742 
Pattern enrichment around nucleosomes  743 
Genomic positions of all hexanucleotide patterns with 6 A or T were identified in GRCh37. 744 
We used nucleosome positions identified in Gaffney at al 80 and determined the distance of 745 
each pattern to the nearest nucleosome center, keeping only those pattern sites within +/- 746 
1500bp around the center. Patterns were classified into three groups: a) AAWWTT motifs b) 747 
AAAAAA, ATATAT and TATATA which showed a distribution distinct from all other patterns 748 
around nucleosome centers and c) all remaining patterns. 749 
 750 
Data analysis and visualization 751 
All visualizations and statistical analyses were produced using R v3.4 81. For all boxplots, the 752 
top, center and bottom of the box correspond to the 75th, 50th (median) and 25th percentile 753 
of all data; the whiskers extend to the most extreme data points, which are no more than 1.5 754 
times the length of the box (i.e., the inter-quartile range) beyond the box. All data points 755 
further away are shown as outliers.  756 
 757 
Reporting Summary 758 
Further information is available from the Life Sciences Reporting Summary linked to this 759 
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Break ends are sampled
 across all genomic sites
of given motif
Motif specific break 
distribution reveals
 break structure
Note that break position
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